Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Lymphoblastic lymphoma (LBL) is a rare and aggressive lymphoblastic neoplasm, accounting for approximately 2% of non-Hodgkin lymphoma cases. Despite sharing clinical and morphological similarities with acute lymphoblastic leukemia (ALL), LBL is characterized by distinct genetic abnormalities. Due to the ambiguity surrounding treatments, the prognosis for LBL remains poor, with complete remission rates between 40-58% and 5-year disease-free survival rates between 36-70%. We present a case of a 42-year-old man diagnosed with B-acute lymphoblastic leukemia (B-ALL)/lymphoblastic lymphoma (LBL). The diagnosis was challenging due to the rarity of the condition and the overlapping features of LBL and ALL. This case report highlights the predominance of lymphoblasts and the presence of the p190 (e1a2) transcript, which is frequently associated with poor prognostic outcomes in lymphoblastic malignancies. The coexistence of both B-ALL and LBL underscores the necessity of a comprehensive understanding of the diagnostic approach, which is essential for optimizing treatment strategies and improving prognosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314840 | PMC |
| http://dx.doi.org/10.25122/jml-2025-0020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Prognostic Scoring Systems for Severe CRS after Anti-CD19 CAR-T-Cells in Acute B-Lymphoblastic Leukemia.
Curr Med Sci
September 2025
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Objective: To develop a novel prognostic scoring system for severe cytokine release syndrome (CRS) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 chimeric antigen receptor (CAR)-T-cell therapy, aiming to optimize risk mitigation strategies and improve clinical management.
Methods: This single-center retrospective cohort study included 125 B-ALL patients who received anti-CD19 CAR-T-cell therapy from January 2017 to October 2023. These cases were selected from a cohort of over 500 treated patients on the basis of the availability of comprehensive baseline data, documented CRS grading, and at least 3 months of follow-up.
Asparaginase Premedication With Hydrocortisone Decreases Hypersensitivity Reactions.
J Pediatr Hematol Oncol
September 2025
Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin.
Background: While pegylated Escherichia coli asparaginase (PEG) is an integral component of leukemia and lymphoma treatment, hypersensitivity reactions (HSR) remain a common adverse event, often resulting in adjustments to the treatment regimen, increasing the burden on patients and families. HSR to asparaginase often indicates a transition to Erwinia asparaginase (ERW), which requires patients to return to the hospital 6 times for subcutaneous injections to replace one dose of IV PEG. Previous trials have demonstrated rates of HSR to pegylated E.
View Article and Find Full Text PDFA Novel Case of Indolent T-Lymphoblastic Proliferation in Metastatic High-Grade Serous Adenocarcinoma.
Int J Lab Hematol
September 2025
Department of Pathology, Odense University Hospital, Odense, Denmark.
Serum SERS Analysis Reveals Amino Acid- and Protein-Associated Vibrational Features for Subtype Identification in Acute Lymphoblastic Leukemia.
Anal Chem
September 2025
Department of Laboratory Medicine, Fujian Medical University, Fuzhou 350004, China.
Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children. Current clinical diagnosis primarily relies on invasive detection methods, while molecular subtyping remains a complex and time-consuming process. This study innovatively employed silver nanoparticle-based surface-enhanced Raman spectroscopy (SERS) technology to systematically analyze 116 serum samples, including those with breakpoint cluster region-Abelson (-) fusion genotype, mixed-lineage leukemia (, also known as lysine methyltransferase 2A, ) gene rearrangement subtype, T-lymphoblastic ALL, and healthy controls.
View Article and Find Full Text PDFLineage Switch of Adult B-Cell Acute Lymphoblastic Leukaemia to Acute Myeloid Leukaemia Following B-Cell-Directed Therapy.
Eur J Case Rep Intern Med
August 2025
Division of Hematology and Oncology, UNM Comprehensive Cancer Center, Albuquerque, USA.
Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially.
View Article and Find Full Text PDF